GV general partner Krishna Yeshwant uses a healthy amount of skepticism when vetting potential companies to invest in. His favorite time to invest is when one of his partners at the fund is excited about a particular company, even if nobody else is. "That’s universally where we’ve had the best returns." In one instance, the GV team couldn't agree on its plan to invest in Foundation Medicine — recently acquired by Roche — and the skepticism from partners within the firm didn't stop. "We continued to disagree all the way through investing in the company," Yeshwant said.